Sumitomo Pharma Co Ltd (STU:DPM)

€ 3.94 -0.04 (-1.01%) Market Cap: 1.60 Bil Enterprise Value: 3.96 Bil PE Ratio: 0 PB Ratio: 1.66 GF Score: 61/100

Q3 2024 Sumitomo Pharma Co Ltd Earnings Presentation Transcript
Jan 31, 2024
Q1 2024 Sumitomo Pharma Co Ltd Earnings Presentation Transcript
Jul 31, 2023
Full Year 2023 Sumitomo Pharma Co Ltd Earnings Presentation Transcript
May 15, 2023
Sumitomo Pharma Co Ltd Midterm 2027 Business Plan Briefing Transcript
Apr 28, 2023
Q3 2023 Sumitomo Pharma Co Ltd Earnings Call Transcript
Jan 31, 2023

Earnings
Sumitomo Pharma Co Ltd ESG Meeting Transcript
Dec 13, 2022
Q2 2023 Sumitomo Pharma Co Ltd Earnings Presentation Transcript
Nov 01, 2022
Q1 2023 Sumitomo Pharma Co Ltd Earnings Call Transcript
Jul 29, 2022

€7.5 (-1.96%)

Earnings
Full Year 2022 Sumitomo Pharma Co Ltd Earnings Presentation Transcript
May 16, 2022
Q3 2022 Sumitomo Dainippon Pharma Co Ltd Earnings Call Transcript
Jan 31, 2022

€9.5 (-5.00%)

Earnings
Sumitomo Dainippon Pharma Co Ltd ESG Briefing Transcript
Dec 08, 2021
Q2 2022 Sumitomo Dainippon Pharma Co Ltd Earnings Presentation Transcript
Oct 28, 2021
Sumitomo Dainippon Pharma Co Ltd Frontier Business Briefing Session Transcript
Sep 08, 2021
Q1 2022 Sumitomo Dainippon Pharma Co Ltd Earnings Call Transcript
Jul 29, 2021

€16 (-3.03%)

Earnings
Full Year 2021 Sumitomo Dainippon Pharma Co Ltd Earnings Presentation Transcript
May 13, 2021
Sumitomo Dainippon Pharma Co Ltd Sumitovant Presentation Transcript
Mar 23, 2021
Q3 2021 Sumitomo Dainippon Pharma Co Ltd Earnings Call Transcript
Jan 28, 2021

€12.2 (+0.83%)

Earnings
Sumitomo Dainippon Pharma Co Ltd ESG Briefing Transcript
Dec 18, 2020
Q2 2021 Sumitomo Dainippon Pharma Co Ltd Earnings Presentation Transcript
Oct 29, 2020
Q1 2021 Sumitomo Dainippon Pharma Co Ltd Earnings Call Transcript
Jul 30, 2020

€10.5 (-0.94%)

Earnings
Full Year 2020 Sumitomo Dainippon Pharma Co Ltd Earnings Presentation Transcript
May 14, 2020
Sumitomo Dainippon Pharma Co Ltd R&D Meeting Transcript
Mar 03, 2020
Q3 2020 Sumitomo Dainippon Pharma Co Ltd Earnings Call Transcript
Jan 30, 2020

€16.2 (-1.22%)

Earnings
Sumitomo Dainippon Pharma Co Ltd ESG Briefing Transcript
Nov 27, 2019
Q2 2020 Sumitomo Dainippon Pharma Co Ltd Earnings Presentation and Definitive Agreement for Strategic Alliance with Roivant Sciences Transcript
Nov 01, 2019
Sumitomo Dainippon Pharma Co Ltd and Roivant Sciences Ltd Memorandum of Understanding for Strategic Alliance Call Transcript
Sep 06, 2019
Q1 2020 Sumitomo Dainippon Pharma Co Ltd Earnings Call Transcript
Jul 29, 2019

€15.69 (+0.06%)

Earnings
Full Year 2019 Sumitomo Dainippon Pharma Co Ltd Earnings Presentation Transcript
May 13, 2019
Sumitomo Dainippon Pharma Co Ltd Mid-Term Business Plan 2022 Presentation Transcript
Apr 12, 2019

Sumitomo Pharma Co Ltd Midterm 2027 Business Plan Briefing Transcript

Apr 28, 2023 / 04:00AM GMT

Release Date Price: €5.6

Transcript

Hiroshi Nomura

Sumitomo Pharma Co., Ltd. - CEO, President & Representative Director

Hello, everyone. My name is Hiroshi Nomura. Thank you very much for taking time out of your busy schedule, to attend or participate today. We issued several press releases at 1 p.m. In addition to the press release for the midterm business plan 2027, we issued the press releases regarding the earnings forecast for FY 2022 and the related dividend and then the dividend for FY 2023.

In FY 2022, there were two major impairment losses. And due to these impairment losses, we managed to keep core operating profit in the black, but the net profit attributable to owners of the parent company was in the red. For FY 2022, we will pay a reduced year-end dividend of JPY 7 per share instead of the usual JPY 14 per share.

And for FY 2023, we have announced the decision of paying no dividend due to a deficit in core operating profit. I'm sorry for this performance. We will strive to improve our business performance by firmly implementing our midterm business plan, which I will explain in the following slides.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.